First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate
Article Sidebar
Main Article Content
Abstract
-
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
1. Dhooria S, Singh Sehgal I, Agarwal R, et al. High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: A randomised trial (SARCORT trial). Eur Respir J 2023;62(3):2300198. https://doi.org/10.1183/13993003.00198-2023
2. Kahlmann V, Janssen Bonás M, Moor CC, et al. First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate. N Engl J Med 2025;393(3):231-242. https://doi.org/10.1056/NEJMoa2501443
3. ick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55(1):19-26. https://doi. org/10.1002/art.21705